Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5241]

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

Oral molecular glue degrader with or without spartalizumab shows immune...

Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain

Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours ( Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain )

ctDNA positivity predicts poor response and recurrence risk in triple-negative...

Dr Priya Rastogi - NSABP Foundation & University of Pittsburgh School of...

ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer ( Dr Priya Rastogi - NSABP Foundation & University of Pittsburgh School of Medicine, Pittsburgh, USA )

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS...

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer ( Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA )

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas ( Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA )

DLL3 expression in circulating tumour cells predicts response to tarlatamab in...

Dr Avanish Mishra - Krantz Family Center for Cancer Research, Boston, USA

DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer ( Dr Avanish Mishra - Krantz Family Center for Cancer Research, Boston, USA )

Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune...

Dr Angelica Loskog - Uppsala University, Uppsala, Sweden

Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer ( Dr Angelica Loskog - Uppsala University, Uppsala, Sweden )

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in...

Dr Manuel Hidalgo - NYU Langone Health, New York, USA

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer ( Dr Manuel Hidalgo - NYU Langone Health, New York, USA )

ctDNA predicts early treatment response in HPV-associated anal cancer

Dr Phebe Mawuena Afi Havor - Moffitt Cancer Center, Tampa, USA

ctDNA predicts early treatment response in HPV-associated anal cancer ( Dr Phebe Mawuena Afi Havor - Moffitt Cancer Center, Tampa, USA )

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal...

Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer ( Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA )

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck...

Dr Enrique Sanz-Garcia - UHN Princess Margaret Cancer Centre, Toronto, Canada

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer ( Dr Enrique Sanz-Garcia - UHN Princess Margaret Cancer Centre, Toronto, Canada )

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )

More from ecancer